KSR2基因3'UTR双荧光素酶报告基因载体构建及其与hcmv-miR-UL70-3p和hcmv-miR-US4-3p靶向关系验证

人巨细胞病毒(Human cytomegalovirus,HCMV)的miR-UL70-3p和miR-US4-3p是HCMV microRNA(miRNA)家族中的一员,前期经生物信息学分析发现,Ras激酶抑制剂2(Kinase Suppressor 2 of Ras,KSR2)的3'-UTR区为miR-UL70-3p和miR-US4-3p的高度可疑结合靶点.为进一步鉴定miR-UL70-3p和miR-US4-3p与KSR2基因的靶标关系,本研究通过构建GV272-KSR2-3'UTR野生和突变型载体,进行双荧光素酶(Luciferase)报告基因实验,并测定其荧光值活性的方法判定miR-UL70-3p和miR-US4-3p是否能与KSR2基因结合.先将293T细胞复苏、扩增并进行质粒转染,转染分6组,每组重复做3孔,分组分别为①KSR2-3'UTR阴性载体与miRNA无关序列载体②KSR2-3'UTR阴性载体与miRNA有效序列载体③KSR2-3'UTR野生序列载体与miRNA无关序列载体④KSR2-3'UTR野生序列载体与miRNA有效序列载体⑤KSR2-3'UTR突变序列载体与miRNA无关序列载体⑥KSR2-3'UTR突变序列载体与miRNA有效序列载体.酶切及DNA测序结果显示GV272-KSR2-3'UTR双荧光素酶报告基因载体构建成功.Luciferase检测显示:同一Luciferase质粒转染的两个组中,将miRNA-NC组Luciferase相对表达量均一化为1,即将实验组①③⑤均一化为1后,比较实验组③和④组、⑤和⑥组、④和⑥组之间的Luciferase检测结果,显示实验组④和实验组③相比,有显著性降低(P＜0.05),实验组⑥和实验组⑤相比,实验组⑥和实验组④相比,差异具有统计学意义(P＜0.05),说明hcmv-miR-UL70-3p和hcmv-miR-US4-3p可与KSR2-3'UTR结合,抑制KSR2表达.     

神经胶质瘤细胞ATF5表达水平对HCMV复制的影响

人巨细胞病毒(human cytomegalovirus,HCMV)在神经胶质瘤细胞中的复制水平不一,其机制尚不清楚。本研究通过下调转录激活因子5(ATF5)在神经胶质瘤细胞中的表达,检测HCMV感染神经胶质瘤细胞后病毒复制水平的变化。首先用HCMV AD169(MOI=5)分别感染U87、SY5Y及A172细胞,观察细胞形态变化,分别在24、48、72、96、120 h取各时间点上清液检测病毒滴度;Real-time PCR检测HCMV即刻早期基因(IE2)、早期基因(UL44)、晚期基因(UL99)及ATF5的表达情况;Western-blot检测病毒基因编码蛋白及ATF5表达的情况。结果显示HCMV在U87、SY5Y细胞中复制水平与病毒在A172细胞中复制水平相比,U87、SY5Y细胞组明显高于A172细胞组(P0.05),ATF5表达在U87、SY5Y细胞组与A172细胞组相比,U87、SY5Y细胞组ATF5表达明显高于A172组(P0.05);利用慢病毒介导的RNA干扰技术下调ATF5在U87、SY5Y细胞的表达,用HCMV感染细胞检测病毒基因及蛋白的表达,结果ATF5表达下调可抑制HCMV的复制(P0.05)。以上结果表明,在胶质瘤细胞中下调ATF5表达水平可以抑制HCMV的复制水平。     

重组禽腺联病毒介导的miRNA抑制传染性法氏囊病病毒在鸡胚内的复制

【目的】在鸡胚水平上探索VP1和VP2基因特异miRNA抑制传染性法氏囊病病毒(infectious bursaldisease virus,IBDV)复制的可行性。【方法与结果】将表达VP1基因特异miRNA重组载体pAITR-RFPmiVP1或VP2基因特异miRNA重组载体pAITR-RFPmiVP2E与禽腺联病毒(avian adeno-associated virus,AAAV)包装载体pcDNA-ARC和腺病毒辅助载体pHelper共转染AAV-293细胞,获得重组病毒rAAAV-RFPmiVP1和rAAAV-RFPmiVP2E,用同样方法获得不表达miRNA的rAAAV-RFP和表达对照miRNA的rAAAV-RFPmiVP2con。电镜观察显示重组病毒具有典型的AAAV颗粒形态;PCR检测结果表明其基因组中含miRNA表达盒;经poly(A)加尾RT-PCR检测证明重组病毒感染细胞能表达基因特异的miRNA。分别将重组病毒经卵黄囊途径接种8日龄SPF鸡胚,然后经绒毛尿囊膜途径用Lukert株IBDV攻毒,收获鸡胚进行IBDV组织细胞半数感染剂量(TCID50)测定。结果在攻毒后第3天,rAAAV-RFP和rAAAV-RFPmiVP2con接种组的IBDV TCID50为8.0 log10,rAAAV-RFPmiVP1和rAAAV-RFPmiVP2E接种组的IBDV TCID50分别下降到1.0和1.5 log10;在攻毒后第6天,rAAAV-RFP和rAAAV-RFPmiVP2con接种组的IBDV TCID50仍为8.0 log10,rAAAV-RFPmiVP1和rAAAV-RFPmiVP2E接种组的TCID50分别下降到0.8和2.0 log10。【结论】rAAAV是有效的miRNA鸡胚导入载体,表达的VP1和VP2基因特异miRNA能有效阻断IBDV复制。     

Mirtron类microRNA6894-5p过表达促进胃癌细胞的迁移、侵袭和增殖

该文主要探讨Mirtron类micro RNA6894-5p过表达对胃癌细胞迁移、侵袭和增殖的影响。将miRNA6894-5p的模拟物分别转染进入胃癌MGC803和SGC7901细胞中,构建miRNA6894-5p过表达的细胞系;实时荧光定量PCR测miRNA6894-5p的RNA表达;Transwell实验检测细胞迁移侵袭能力;Cell Counting Kit 8实验检测细胞的增殖能力;荧光素酶报告基因实验检测miRNA6894-5p与肝配蛋白A3的靶向关系;实时荧光定量PCR和蛋白质印迹法进一步检测miRNA6894-5p过表达后EFNA3的m RNA和蛋白的变化。结果显示,成功构建miRNA6894-5p过表达模型的胃癌细胞系;与相应阴性对照组相比,过表达miRNA6894-5p可提高细胞迁移侵袭能力(P0.05)和增强细胞增殖能力(P0.05);荧光素酶报告基因实验证实,miRNA6894-5p靶向作用于肝配蛋白A3,过表达miRNA6894-5p后肝配蛋白A3的m RNA及蛋白水平显著下降(P0.05)。该研究结果显示,Mirtron类miRNA6894-5p在人胃癌细胞中过表达可促进胃癌细胞的迁移、侵袭和增殖。     

利用CRISPR/Cas9n系统敲除人源SNF5基因

目的:建立敲除人源基因组中SNF5基因的CRISPR/Cas9n系统。方法:设计一对靶向人源SNF5基因第1个外显子的sg RNA,分别克隆至p X461、p X462表达载体后,转入人胚肾293T细胞,通过Western印迹检测细胞株中SNF5基因的敲除效果。结果:测序证明构建的靶向SNF5基因CRISPR/Cas9n重组质粒与设计吻合。Western印迹结果显示,重组质粒p X461-h SNF5sg RNA转染293T细胞后24 h,细胞内SNF5表达水平明显降低;重组质粒p X462-h SNF5sg RNA转染293T细胞后48 h,细胞内SNF5表达水平显著降低。结论:通过CRISPR/Cas9n系统获得了靶向SNF5基因的重组质粒,构建的重组质粒能有效敲除SNF5基因的表达。     

miR-196b-5p促进成肌细胞增殖分化

MicroRNA (miRNA)是一类由内源基因编码的长度约为22个核苷酸的非编码单链RNA分子，在动植物中参与转录后基因表达调控。大量研究表明，miRNA调控骨骼肌的发育，主要表现在肌卫星细胞的激活及增殖、分化、肌管的形成等生物学过程。本实验室前期对大白猪背最长肌(longissimus dorsi,LD)和比目鱼肌(soleus muscle,Sol)进行miRNA测序，筛选鉴定到一个在不同骨骼肌中差异表达并且序列高度保守的miR-196b-5p，目前miR-196b-5p在骨骼肌方面的研究尚未见报道。本研究进一步设计合成miR-196b-5p mimics和inhibitor对C2C12细胞进行miR-196b-5p过表达及干扰表达，利用蛋白免疫印迹、实时荧光定量PCR检测、流式细胞术、免疫荧光染色等方法探究miR-196b-5p对成肌细胞增殖分化的影响，并利用生物信息学预测和双荧光素酶报告系统鉴定了miR-196b-5p的靶基因。结果显示，过表达miR-196b-5p显著增加细胞周期基因Cyclin B、Cyclin D和Cyclin E的mRNA和蛋白表达水平(P<0....     

含p53保守结合位点的microRNA表达载体的构建及应用

目的:构建含p53保守结合位点的microRNA(miRNA)表达载体,促进相关miRNA在具有野生型p53蛋白细胞中的高效表达。方法:改构miRNA表达载体pCMV-miR,在其多克隆位点前插入p53保守结合位点,分别将miR-138、miR-34a和miR-21前体序列pre-miR-138、pre-miR-34a和pre-miR-21插入上述改构的载体pCMV/p53-miR,将构建的pCMV/p53-miR-138、pCMV/p53-miR-34a和pCMV/p53-miR-21表达载体转染具有野生型p53的HeLa细胞和不表达p53的H1299细胞,分析p53对上述miRNA表达调控的影响。结果:转染改构的miRNA表达载体后,HeLa细胞中miR-138、miR-34a和miR-21的表达水平明显提高,它们对应的已知靶基因Cyclin D3、CDK2和PTEN的表达同时被显著下调。结论:在p53转录调控作用下,具有p53保守结合位点的miRNA表达载体能够更加有效地提高miRNA的表达水平;构建的载体不但可用于促进相关miRNA的表达,也能用于miRNA是否受p53调控的检测。     

HCMV感染对恶性胶质瘤U87细胞增殖及ATF5表达的影响

人巨细胞病毒(HCMV)能够诱导肿瘤细胞的恶性转化,但其分子机制尚有待进一步探索。探讨HCMV是否通过调控转录激活因子5(ATF5)的表达变化促进胶质瘤细胞的增殖。采用HCMV AD169株(MOI=5)感染神经胶质瘤U87细胞株,MTT方法观察HCMV感染0、12、24、48 h后细胞的增殖活性。Real-time PCR及Western-blot检测HCMV感染U87细胞后ATF5基因及蛋白的表达水平变化。以慢病毒为载体的靶向ATF5小干扰RNA构建载体,敲低ATF5表达水平后感染HCMV,MTT检测病毒感染细胞的增殖活性变化。HCMV感染神经胶质瘤U87细胞后,与未感染组比较,增值活性明显升高(P0.05),ATF5表达水平上升,表明HCMV感染使胶质瘤细胞增殖活性提高,细胞抗凋亡能力增强。成功构建沉默ATF5细胞系siATF5 U87,HCMV感染siATF5 U87细胞后使细胞增殖活性减弱,抗凋亡能力下降。以上实验结果表明,HCMV感染上调胶质瘤U87细胞ATF5的表达水平,促进细胞的增殖。因此HCMV感染可能通过调控ATF5信号通路增加细胞恶性性状,为治疗胶质瘤提供一个新的思路。     

利用RNA干扰抑制p21WAF1/CIP1基因的表达及周期阻滞效应

目的：构建p21WAF1/CIP1基因小干扰RNA（siRNA）的真核表达载体,观察其对p21WAF1/CIP1表达的影响和细胞周期的变化。方法：合成了针对p21WAF1/CIP1基因的siRNA,将其克隆到siRNA表达载体pSliencer2.1-U6neo上,将重组质粒和带FLAG标签的p21WAF1/CIP1共转染293T人胚肾细胞,通过Westernblot检验RNA干扰（RNAi）敲低外源p21WAF1/CIP1的效果;将重组质粒单独转染293T人胚肾细胞,利用p21WAF1/CIP1抗体检测RNAi敲低内源p21WAF1/CIP1的效果;利用流式细胞仪检测敲低后细胞周期的变化。结果：测序证明构建了p21WAF1/CIP1siRNA真核表达载体;Westernblot和流式细胞分析证明,构建的siRNA能有效降低p21WAF1/CIP1基因的表达,并且使G1期细胞数减少14.03%,S期细胞增多13.45%。结论：构建了p21WAF1/CIP1siRNA的真核表达载体,该siRNA能有效抑制p21WAF1/CIP1基因的表达并部分解除了G1期阻滞。     

siRNA靶向沉默p22phox表达对内皮细胞衰老抑制作用的研究

设计特异性siRNA(Short interference RNA)诱导人脐静脉内皮细胞株ECV-304细胞NAD(P)H氧化酶活性亚单位p22phox基因沉默, 探讨p22phox基因沉默在血管紧张素Ⅱ(AngⅡ)诱导的ECV-304衰老中的作用及机理。应用体外转录合成3种siRNA转染体外培养的ECV-304, RT-PCR鉴定对p22phox基因沉默的效率和特异性, 确立适宜的转染浓度和基因沉默的持续时间; ECV-304分为空白对照组、AngⅡ组、siRNA转染组、AngⅡ+siRNA转染组, 观察细胞衰老改变及活性氧水平, 分析各组细胞p22phox的mRNA及蛋白表达。结果表明: 3种siRNA中, 一种对p22phox mRNA表达抑制率达到83％, 在一定转染浓度范围内, siRNA诱导的基因沉默效率呈剂量依赖性, 抑制效率高峰期在24~36 h; 给予AngⅡ后, b-gal染色阳性细胞数显著增加, 出现衰老的特征性改变, 衰老细胞p22phox的 mRNA及蛋白表达增加, 伴有一氧化氮(NO)生成减少, 活性氧生成增加, siRNA诱导p22phox基因沉默后降低了活性氧水平, 增加NO生成, 改善了AngⅡ诱导的ECV-304细胞的衰老改变。siRNA干扰技术可成功诱导NAD(P)H氧化酶p22phox基因沉默, 从而减缓AngⅡ诱导体外培养的ECV-304衰老进程, p22phox是防治衰老有希望的分子靶点。     

Human Cytomegalovirus miR-UL112-3p Targets TLR2 and Modulates the TLR2/IRAK1/NFκB Signaling Pathway

Human Cytomegalovirus (HCMV) encodes multiple microRNAs (miRNAs) whose functions are just beginning to be uncovered. Using in silico approaches, we identified the Toll-Like Receptor (TLR) innate immunity pathway as a possible target of HCMV miRNAs. Luciferase reporter assay screens further identified TLR2 as a target of HCMV miR-UL112-3p. TLR2 plays a major role in innate immune response by detecting both bacterial and viral ligands, including HCMV envelope proteins gB and gH. TLR2 activates a variety of signal transduction routes including the NFκB pathway. Furthermore, TLR2 plays an important role in controlling CMV infection both in humans and in mice. Immunoblot analysis of cells transfected with a miR-UL112-3p mimic revealed that endogenous TLR2 is down-regulated by miR-UL112-3p with similar efficiency as a TLR2-targeting siRNA (siTLR2). We next found that TLR2 protein level decreases at late times during HCMV infection and correlates with miR-UL112-3p accumulation in fibroblasts and monocytic THP1 cells. Confirming direct miR-UL112-3p targeting, down-regulation of endogenous TLR2 was not observed in cells infected with HCMV mutants deficient in miR-UL112-3p expression, but transfection of miR-UL112-3p in these cells restored TLR2 down-regulation. Using a NFκB reporter cell line, we found that miR-UL112-3p transfection significantly inhibited NFκB-dependent luciferase activity with similar efficiency as siTLR2. Consistent with this observation, miR-UL112-3p transfection significantly reduced the expression of multiple cytokines (IL-1β, IL-6 and IL-8) upon stimulation with a TLR2 agonist. Finally, miR-UL112-3p transfection significantly inhibited the TLR2-induced post-translational activation of IRAK1, a kinase located in the upstream section of the TLR2/NFκB signaling axis. To our knowledge, this is the first identified mechanism of TLR2 modulation by HCMV and is the first report of functional targeting of TLR2 by a viral miRNA. These results provide a novel mechanism through which a HCMV miRNA regulates the innate immune response by down-regulating TLR-2 expression.     

Human Cytomegalovirus Clinical Strain-Specific microRNA miR-UL148D Targets the Human Chemokine RANTES during Infection

The human cytomegalovirus (HCMV) clinical strain Toledo and the attenuated strain AD169 exhibit a striking difference in pathogenic potential and cell tropism. The virulent Toledo genome contains a 15-kb segment, which is present in all virulent strains but is absent from the AD169 genome. The pathogenic differences between the 2 strains are thought to be associated with this additional genome segment. Cytokines induced during viral infection play major roles in the regulation of the cellular interactions involving cells of the immune and inflammatory systems and consequently determine the pathogenic outcome of infection. The chemokine RANTES (Regulated on activation, normal T-cell expressed and secreted) attracts immune cells during inflammation and the immune response, indicating a role for RANTES in viral pathogenesis. Here, we show that RANTES was downregulated in human foreskin fibroblast (HFF) cells at a later stage after infection with the Toledo strain but not after infection with the AD169 strain. miR-UL148D, the only miRNA predicted from the UL/b'' sequences of the Toledo genome, targeted the 3′-untranslated region of RANTES and induced degradation of RANTES mRNA during infection. While wild-type Toledo inhibited expression of RANTES in HFF cells, Toledo mutant virus in which miR-UL148D is specifically abrogated did not repress RANTES expression. Furthermore, miR-UL148D-mediated downregulation of RANTES was inhibited by treatment with a miR-UL148D-specific inhibitor designed to bind to the miR-UL148D sequence via an antisense mechanism, supporting the potential value of antisense agents as therapeutic tools directed against HCMV. Our findings identify a viral microRNA as a novel negative regulator of the chemokine RANTES and provide clues for understanding the pathogenesis of the clinical strains of HCMV.     

Human cytomegalovirus blocks canonical TGFβ signaling during lytic infection to limit induction of type I interferons

Human cytomegalovirus (HCMV) microRNAs (miRNAs) significantly rewire host signaling pathways to support the viral lifecycle and regulate host cell responses. Here we show that SMAD3 expression is regulated by HCMV miR-UL22A and contributes to the IRF7-mediated induction of type I IFNs and IFN-stimulated genes (ISGs) in human fibroblasts. Addition of exogenous TGFβ interferes with the replication of a miR-UL22A mutant virus in a SMAD3-dependent manner in wild type fibroblasts, but not in cells lacking IRF7, indicating that downregulation of SMAD3 expression to limit IFN induction is important for efficient lytic replication. These findings uncover a novel interplay between SMAD3 and innate immunity during HCMV infection and highlight the role of viral miRNAs in modulating these responses.     

人巨细胞病毒pp150蛋白片段与MDBP蛋白片段的融合表达及初步应用

人巨细胞病毒(HCMV)感染是临床上常见的一种病毒性传播疾病,正常人群常无明显的临床症状,而对器官移植患者、免疫力低下及孕妇等人可产生严重的危害。以HCMVAD169病毒株基因为模板,经PCR扩增了编码pp150蛋白片段的UL32基因和编码MDBP蛋白片段的UL57基因,目的基因转化入pMD18-T克隆载体后再经酶切与表达载体pET-11a连接构建出融合基因表达载体,然后转入大肠杆菌BL21,重组大肠杆菌经诱导表达融合蛋白pp150/MDBP。经SDS-PAGE分析,其相对分子量约为27kD,表达量约占菌体蛋白的17.45%,Westernblot鉴定为阳性,ELISA及蛋白芯片检测表明融合蛋白具有良好的抗原性,经过初步应用表明其对血清IgG及IgM的检出率与全抗原相比一致,具有进一步开发应用的价值。     

HCMV截短UL83基因真核表达重组体的构建、转染及其免疫效力研究

为了构建人巨细胞病毒(HCMV)截短UL83基因真核表达重组体,实现其在Hep-2细胞中的稳定表达,研究该截短UL83基因真核表达重组体免疫效力,采用基因重组的方法,将HCMV AD169株截短UL83基因定向克隆到带有绿色荧光蛋白(GFP)作为报告基因的真核表达载体pEGFP-C1上,构建真核重组表达质粒pEGFP-C1-UL83;脂质体转染至Hep-2细胞中,G418筛选获得稳定表达pp65细胞表达系。经基因测序显示,重组体中截短UL83基因完全正确,RT-PCR和Western blot检测证实其可在Hep-2细胞中稳定表达。用该重组体和其表达产物在HCMV先天性感染小鼠模型上进行免疫保护试验显示,母鼠血清可检测到特异性抗HCMV pp65抗体,效价为:1∶2.51~1∶50.79;子鼠脑组织内未分离出病毒,亦未检测出病毒pp65蛋白抗原表达。初步结果表明,pEGFP-C1-UL83具有较好的免疫原性,可作为DNA疫苗刺激机体产生有效抗体,并具有阻止病毒垂直传播的保护性作用。